ArticleBMC ophthalmology2026
Adjuvant mitomycin C during vitrectomy in young adults with primary nontraumatic rhegmatogenous retinal detachment and grade C proliferative vitreoretinopathy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProliferative vitreoretinopathy (PVR) complicates 5-10% of rhegmatogenous retinal detachments (RRD) and remains a major cause of surgical failure. Intraoperative mitomycin C (MMC), a potent antiproliferative agent, may suppress postoperative PVR formation. This study evaluated the anatomical, functional, and safety outcomes of intraoperative MMC in young adults with primary RRD complicated by grade C PVR.
methodsThis retrospective cohort study included 126 eyes of patients aged 18-45 years with primary nontraumatic RRD and grade C PVR. All eyes underwent 25-gauge pars plana vitrectomy with silicone oil tamponade. Intraoperative MMC was administered in 61 eyes, while 65 eyes served as controls. The primary outcome was single-surgery anatomical success at 6 months. Secondary outcomes included final retinal reattachment, PVR progression, best-corrected visual acuity (BCVA), intraocular pressure (IOP) changes, silicone oil removal, and MMC-related adverse events.
resultsMMC-treated eyes showed significantly lower rates of postoperative PVR progression and reoperation than controls (P < 0.05). Primary and final reattachment rates and BCVA improvement were higher in the MMC group, although differences did not reach statistical significance. No clinically detectable retinal or optic nerve toxicity attributable to MMC was observed. Rates of elevated IOP, hypotony, cystoid macular edema, and intraocular inflammation were comparable between groups.
conclusionsIntraoperative adjuvant MMC was associated with reduced postoperative PVR progression and reoperation rates in young adults with primary RRD and grade C PVR. A favorable trend was also observed in anatomical and visual outcomes, suggesting that MMC may represent a promising adjunctive treatment strategy in selected high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.